Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01650948 · ClinicalTrials.gov registry record
Genetic Load and Phenotype in Aggressive AMD
A clinical trial of Age-related Macular Degeneration, sponsored by Sequenom.
- Completed
- Registry status
- 100
- Enrollment target
- 3
- Study locations
NCT01650948: Completed study of Age-related Macular Degeneration, sponsored by Sequenom.
NCT01650948 is a study of Age-related Macular Degeneration that has completed, run by Sequenom. The registered enrollment target is 100 participants, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01650948, a study of Age-related Macular Degeneration, has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).
Conditions Studied
Interventions
- DEVICE RetnaGene AMD LDT
Study Locations (3)
California
- Pacific Eye Associates - San Francisco
Kentucky
- Retina Associates of Kentucky - Lexington
Tennessee
- Tennessee Retina - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-12 |
What the finished NCT01650948 record still lists
NCT01650948 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which RetnaGene AMD LDT is the first listed.
NCT01650948 reports a single indexed study location in California, Kentucky, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01650948 about?
NCT01650948 is a clinical study titled "Genetic Load and Phenotype in Aggressive AMD". Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).
What is the current status of trial NCT01650948?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2012-07. Estimated completion is 2013-12.
What conditions does trial NCT01650948 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT01650948?
The interventions under investigation include: RetnaGene AMD LDT (DEVICE).
Who is sponsoring clinical trial NCT01650948?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01650948 being conducted?
This trial has 3 study locations across California, Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01650948's enrollment target sits among peer trials
100 31st of 74 higher than 42 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia